About Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals is engaged in developing, manufacturing and marketing a broad range of pharmaceutical products globally.
Founded
1981
CEO
SATISH RAMANLAL MEHTA
Employees
11,474
HQ
Pune, India
Finished Products
1Sale of Products
₹10,873.57Cr2Other Operating Income
₹46.77Cr3Government Grant
₹28.33Cr4Sale of Services
₹18.88Cr5Export incentives
₹13.08Cr6Scrap Sales
₹4.32Cr7Indirect tax refund received
₹1.72CrRaw Materials
1Raw Material Consumed
₹3,053.02Cr2Purchase of Traded Goods
₹1,462.93Cr3Packing Material Consumed
₹281.64CrAbout Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals is engaged in developing, manufacturing and marketing a broad range of pharmaceutical products globally.
Founded:1981
CEO:SATISH RAMANLAL MEHTA
Employees:11,474
HQ:Pune, India
Finished Products
1Sale of Products
₹10,873.57Cr2Other Operating Income
₹46.77Cr3Government Grant
₹28.33Cr4Sale of Services
₹18.88Cr5Export incentives
₹13.08Cr6Scrap Sales
₹4.32Cr7Indirect tax refund received
₹1.72CrRaw Materials
1Raw Material Consumed
₹3,053.02Cr2Purchase of Traded Goods
₹1,462.93Cr3Packing Material Consumed
₹281.64CrPrice Performance & Market EventsPrice Performance
Loading chart data…
Key Metrics
Trading & valuation snapshot
52W High
₹2,048
52W Low
₹1,260
Volume93.73K
Avg VolumeN/A
Beta0.49
Dividend Yield0.19%
Key Financial Ratios
Profitability, leverage & efficiency at a glance
P/E Ratio
34.58x
Valuation
P/B Ratio
7.12x
Valuation
EPS
₹53.71
Valuation
Dividend Yield
0.19%
Valuation
ROE
18.67%
Profitability
ROCE
21.76%
Profitability
Revenue by Segment
Contribution & growth by business line
Pharmaceutical ProductsRevenue split N/A
Geographical Revenue Split
Domestic vs international exposure
Domestic
43.8%
International
56.2%
Within India43.8%
Europe20.1%
Other continents20.0%
North America16.2%
Strategic Relations
Collaborations, joint ventures & subsidiaries
No collaborations data available.
Forensic Metrics
Financial health & earnings-quality indicators
Revenue Quality
N/A
Days Sales Outstanding
Leverage
0.31x
Debt-to-Equity
Earnings Quality
N/A
Cash Conversion Ratio
Efficiency
N/A
Asset Turnover
Earnings Quality
N/A
Accruals Ratio
Profitability
N/A
Gross Margin
Growth
11.4%
Sales Growth
These metrics are derived from available financial disclosures and market data. Use them together with company filings and qualitative analysis before making decisions.